Foundation Medicine and partners Flatiron Health and Genentech are highlighting clinical results that show the value of tissue and liquid genomic profiling in patients with advanced non-small cell lung cancer.
The findings are from the Prospective Clinicogenomic (PCG) study and were published August 5 in the Journal of Thoracic Oncology Clinical and Research Reports.
A team led by Dr. Shannon Zhangh of the University of California Irvine School of Medicine compared the performance of Foundation Medicine's FoundationOne CDx and FoundationOne Liquid CDx genomic profiling kits to standard tissue testing for identifying biomarkers for treatment planning in patients with advanced non-squamous non-small cell lung cancer.
The study showed that FoundationOne CDx and FoundationOne Liquid CDx offered better biomarker detection over limited tissue testing of up to five biomarkers, the company said.